Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)’s share price was down 6.3% on Tuesday . The company traded as low as $3.94 and last traded at $4.01. Approximately 2,125,784 shares traded hands during trading, an increase of 13% from the average daily volume of 1,880,325 shares. The stock had previously closed at $4.28.
A number of analysts have weighed in on CPRX shares. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Thursday, February 18th. Piper Sandler cut their target price on Catalyst Pharmaceuticals from $6.00 to $5.50 and set an “overweight” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $7.83.
The firm has a 50-day simple moving average of $3.86 and a two-hundred day simple moving average of $3.49. The company has a market capitalization of $416.15 million, a price-to-earnings ratio of 6.39 and a beta of 1.53.
About Catalyst Pharmaceuticals (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.
Recommended Story: VIX – Volatility Index
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.